Work Packages
KNOW THE
African swine fever (ASF) is a devastating infectious disease in pigs – usually deadly. No vaccine exists to combat this virus. The European Union has laid down prevention and control measures to be applied where African swine fever is suspected or confirmed, either in holdings or in wild boars.
The EU-funded VACDIVA project will provide three safe and effective pilot vaccines for wild boars and domestic pigs that is ready for registration. It will also validate DIVA tests and develop cost-benefit and -effective surveillance and control-vaccination strategies.
WP1 Coordination and management
(MONTHS: 1-48)
To coordinate and manage the scientific, administrative, communicative and financial aspects of the project in accordance with grant agreement and the decisions taken by the consortium.
Leader: UCM
PARTNERS INVOLVED: INIA – MAH – INGENASA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI – IZSUM – FMV – MPG – WR – FGI ARRIAH – IASCAAS – ILRI – CAHEC – ECVC – HORIZCIENCE.
WP2 ASF modified DIVA Vaccine
(MONTHS: 1-42)
To develop further attenuated safer vaccine prototypes (LAVs) with marker properties from the original vaccine candidates by genome editing.
Leader: NFCSO
PARTNERS INVOLVED: INIA – MAH – INGENASA – IZS – NFCSO – FMV – FGI ARRIAH.
WP3 LAV Lv17/Rie1 DIVA Vaccine for Wild Boar. Efficacy and safety studies. “in vivo” experiments.
(MONTHS: 1-42)
To carry out the “in vivo” testing requirements needed following EMA regulations to prepare a final Lv17/WB/Rie1 LAV vaccine prototype for wildboar, and to design of the vaccination formula to be delivered in the field.
Leader: UCM
PARTNERS INVOLVED: INIA – MAH – NFCSO.
WP4 Efficacy and safety studies of marker vaccines
(MONTHS: 12-42)
To select the most promising marker vaccine/s built under WP2 throughout “in vivo” experimental efficacy and safety studies in domestic pigs (DP) as animal model for vaccination.
Leader: INIA
PARTNERS INVOLVED: INIA – MAH – INGENASA – IZS – NFCSO – IZSUM – FMV – FGI ARRIAH.
WP5 Vaccine production
(MONTHS: 6-48)
To develop a manufacturing process for the prototype vaccine/s with the immunological products previously tested under WP2, WP3 and WP4, safe and effective enough following the requirements of the European Medicine Agency and authorizing agencies of countries outside EU.
Leader: MAH
PARTNERS INVOLVED: INIA – NFCSO – IZSUM – FMV – FGI ARRIAH.
WP6 Development of companion DIVA tests to the candidate vaccines: Evaluation and validation.
(MONTHS: 1-48)
To develop companion DIVA tests, associated with the prototype vaccines, that will allow the differentiation of vaccinated from infected animals. All assays will be adapted to be used with wild boar and domestic pig samples.
Leader: INGENASA
PARTNERS INVOLVED: UCM – INIA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI – IZSUM – FMV – FGI ARRIAH – IASCAAS – HORIZCIENCE.
WP7 Control of ASF in diferent scenarios: Vaccination and spread models + Field trials
(MONTHS: 1-48)
To identify the differents vaccination scenarios from ASF prevention or control, frame the target vaccination populations in each scenario and model different vaccine and control strategies to obtain a roadmap with the most cost-efficient methods towards ASF control with vaccination.
Leader: UCM
PARTNERS INVOLVED: INIA – INGENASA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI – MPG – WR – ILRI – CAHEC.
WP8 Exploitation and Innovation Management
(MONTHS: 1-48)
- Manage IP and innovation.
- Facilitate agreements for the protection and exploitation of the results.
- Ensure and efficient exploitation and disemination of the results of the project.
- Update business plans and identify exploitation and dissemination activities and updte them regularly.
- Follow-up risks for the exploitation of results.
- Engage stakeholders.
Leader: HORIZCIENCE
PARTNERS INVOLVED: UCM – INIA – MAH – INGENASA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI – IZSUM – FMV – MPG – WR – FGI ARRIAH – IASCAAS – ILRI – CAHEC – ECVC.
WP9 Communication
(MONTHS: 1-48)
To communicate the objectives, activities and results of the project in the most efficient way. This WP will establish and develop a comprehensive, modern and effective communication plan.
The partners will provide, beyond scientific publications, information of the relevant progress of the different tasks of the project in order to inform the stakeholders and other relevant actors.
Leader: HORIZCIENCE
PARTNERS INVOLVED: UCM – INIA – MAH – INGENASA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI´ – IZSUM – FMV – MPG – WR – FGI ARRIAH – IASCAAS – ILRI – CAHEC – ECVC.
WP10 Ethics requirements
(MONTHS: 1-48)
To set out the “ethics requirements” that the project must complay with.
Leader: UCM
PARTNERS INVOLVED: INIA – MAH – INGENASA – IZS – NFCSO – VFL – SVI – BIOR – NFVRAI´ – IZSUM – FMV – MPG – WR – FGI ARRIAH – IASCAAS – ILRI – CAHEC – ECVC – HORIZCIENCE.